Comparison of Two Treatment Regimens to Reduce PA Infection in Children With Cystic Fibrosis (EPIC)

This study has been completed.
Sponsor:
Collaborators:
Cystic Fibrosis Foundation
CF Therapeutics Development Network Coordinating Center
Information provided by (Responsible Party):
Bonnie Ramsey, Seattle Children's Hospital
ClinicalTrials.gov Identifier:
NCT00097773
First received: November 30, 2004
Last updated: January 28, 2014
Last verified: January 2014

November 30, 2004
January 28, 2014
September 2004
June 2009   (final data collection date for primary outcome measure)
Number of Participants With a Pulmonary Exacerbation Requiring IV Antibiotics or Hospitalization [ Time Frame: Measured over the 18 month study ] [ Designated as safety issue: No ]

The primary comparison is between the pooled culture-based group and the pooled cycled group. A secondary comparison is between the pooled ciprofloxacin group vs the pooled placebo group. Descriptive results are provided for the pooled treatment groups.

Participants are represented once in the cycled and culture-based therapy columns, and once in the cipro and placebo columns.

Not Provided
Complete list of historical versions of study NCT00097773 on ClinicalTrials.gov Archive Site
  • Proportion of Participants With a Pa Positive Culture [ Time Frame: Week 10 (after initial treatment course for Pa) through Month 18 ] [ Designated as safety issue: No ]

    Proportion of participants with a Pa positive culture compared between (1) the pooled cycled therapy group (n=152) and pooled culture-based therapy group (n=152), and (2) between the pooled oral placebo (n=152)and pooled cipro groups (n=152).

    Participants are included once in the cycled and culture-based columns, and once in the oral cipro and placebo columns

  • Number of Participants With a Pulmonary Exacerbation Requiring Oral, Inhaled, or Oral Antibiotics [ Time Frame: Measured over the 18 month time period ] [ Designated as safety issue: No ]

    The primary comparison is between the pooled culture-based group and the pooled cycled group. No interactions with ciprofloxacin were identified. A secondary comparison is between the pooled ciprofloxacin group vs the pooled placebo group. Descriptive results are provided for the pooled treatment groups.

    Participants are represented once in the cycled and culture-based therapy columns, and once in the cipro and placebo columns.

Not Provided
Not Provided
Not Provided
 
Comparison of Two Treatment Regimens to Reduce PA Infection in Children With Cystic Fibrosis
Effectiveness and Safety of Intermittent Antimicrobial Therapy for the Treatment of New Onset Pseudomonas Aeruginosa Airway Infection in Young Patients With Cystic Fibrosis

Cystic fibrosis (CF) is a chronic disease that significantly affects an individual's lung function. Antibiotic medications have been proven effective at reducing Pseudomonas aeruginosa (PA) infection, which is one of the main causes of death in individuals with CF. The purpose of this study is to compare the effectiveness of treatment based on quarterly culture results versus consistent quarterly antibiotic treatment at reducing PA infection in children with CF.

CF is an inherited disease that causes mucus to build up in the lungs and digestive tract, which can cause lung infections and digestive problems. It is the most common type of chronic lung disease in children and young adults and may result in early death. There is no cure for this disease. The primary cause of death in individuals with CF is progressive obstructive pulmonary disease associated with chronic Pseudomonas aeruginosa (PA) infection. PA infection can occur early in life and can become highly resistant to antibiotics. Once an individual has been diagnosed with chronic PA infection, it is almost impossible to manage effectively. The need exists for an effective treatment to control and eliminate PA infection. Past research has shown that if PA infection is treated early, there is a greater likelihood that it may be eliminated completely. This study will examine two treatment regimens to compare which is more effective at eliminating PA infection. In the first regimen, participants will receive antibiotic treatment at various times throughout the study, based on findings of PA respiratory cultures obtained on a quarterly basis. In the second regimen, participants will receive antibiotic medications in consistent, quarterly cycles throughout the study. The antibiotic medications used in this study will be ciprofloxacin and inhaled tobramycin, which will be administered with a nebulizer. Both of these medications have been proven effective at treating bacterial lung infections. The overall purpose of this study is to compare the effectiveness of culture-based treatment versus consistent treatment at reducing PA infection in children with CF.

This 18-month study will enroll children with CF. For the first 28 days of the study, all participants will receive inhaled tobramycin. For the initial 14 days of this 28-day period, half of the participants will also receive either ciprofloxacin or placebo. If respiratory cultures after three weeks of treatment confirm the presence of PA, participants will receive tobramycin for an additional 28 days. Participants will then be randomly assigned to one of four treatment options: tobramycin and placebo for six consecutive quarterly cycles; tobramycin and ciprofloxacin for six consecutive quarterly cycles; tobramycin and placebo only when PA is found during quarterly respiratory cultures; or tobramycin and ciprofloxacin only when PA is found during quarterly respiratory cultures.

At the first study visit, participants will undergo a physical examination, a chest x-ray, and a review of their medical history. Lung function will be measured via spirometry (in children greater than four years of age who are able to perform spirometry), and hearing ability will be measured via audiometry (at selected sites). Blood will be drawn for laboratory tests, and a specimen will be obtained for a respiratory culture. Subsequent study visits will take place at Day 21, Weeks 10, 22, 34, 46, 58, and 70. At each visit, participants will undergo a physical examination and a spirometry test (as appropriate), and a respiratory specimen for PA culture and blood will again be collected. Participants will be required to maintain a medication diary throughout the study, and they will be contacted between visits to review medication adherence and test results.

Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
  • Cystic Fibrosis
  • Pulmonary Disease, Chronic Obstructive
  • Drug: Tobramycin solution for inhalation (TOBI)
    Tobramycin solution for inhalation, 300 mg, administered twice daily for 28 days administered only when quarterly respiratory cultures are found positive for Pa.
    Other Name: TOBI, TIS
  • Drug: Oral placebo
    Oral placebo for six consecutive quarterly cycles. For the initial 14 days of the 28-day treatment period, the participants will receive placebo, twice daily.
    Other Name: Placebo
  • Drug: Oral ciprofloxacin
    Oral ciprofloxacin for six consecutive quarterly cycles. For the initial 14 days of the 28-day treatment period, the participants will receive oral ciprofloxacin, 15-20 mg/kg/dose, twice daily.
    Other Names:
    • Cipro
    • Ciprofloxacin
  • Placebo Comparator: Cycled TOBI & placebo
    Tobramycin inhalation solution and oral placebo for six consecutive quarterly cycles
    Interventions:
    • Drug: Tobramycin solution for inhalation (TOBI)
    • Drug: Oral placebo
  • Active Comparator: Cycled TOBI & oral ciprofloxacin
    Tobramycin solution for inhalation and oral ciprofloxacin for six consecutive quarterly cycles.
    Interventions:
    • Drug: Tobramycin solution for inhalation (TOBI)
    • Drug: Oral ciprofloxacin
  • Placebo Comparator: Culture based TOBI & placebo
    Tobramycin solution for inhalation and oral placebo administered only when quarterly respiratory cultures are found positive for Pa.
    Interventions:
    • Drug: Tobramycin solution for inhalation (TOBI)
    • Drug: Oral placebo
  • Active Comparator: Culture based TOBI & oral cipro
    Tobramycin solution for inhalation and oral ciprofloxacin administered only when quarterly respiratory cultures are found positive for Pa.
    Interventions:
    • Drug: Tobramycin solution for inhalation (TOBI)
    • Drug: Oral ciprofloxacin

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
304
August 2009
June 2009   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Diagnosis of CF, as determined by the 1997 CF Consensus Conference criteria: sweat chloride level greater than 60 milliequivalent/liter (mEq/L) by quantitative pilocarpine iontophoresis; or a genotype with two identifiable mutations consistent with CF; or an abnormal nasal transepithelial potential difference and one or more clinical features consistent with CF
  • For participants greater than 15 months of age: documented new onset of positive oropharyngeal, sputum, or lower respiratory tract culture for PA within 6 months of study entry, defined as either: 1) first lifetime documented PA positive culture; or 2) PA recovered after at least a 2-year history of PA negative respiratory cultures (at least one culture per year)
  • For participants 12-15 months of age: at least one documented positive oropharyngeal, sputum, or lower respiratory tract culture for PA since birth or CF diagnosis
  • Clinically stable with no evidence of any significant respiratory symptoms or chest radiograph findings at screening that would require administration of intravenous anti-pseudomonal antibiotics, oxygen supplementation, or hospitalization

Exclusion Criteria:

  • History of aminoglycoside hypersensitivity or adverse reaction to inhaled aminoglycoside
  • History of hypersensitivity or adverse reaction to ciprofloxacin or other fluoroquinolone medications
  • History of persistent, unresolved hearing loss documented by audiometric testing on at least two occasions and not associated with middle ear disease or an abnormal tympanogram
  • Abnormal kidney function at study entry (defined as a serum creatinine level greater than 1.5 times the upper limit of normal for participant's age)
  • Abnormal liver function test results at study entry (defined as alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) levels greater than two times the upper limit of normal range)
  • Use of any investigational drug within 30 days of study entry
  • Use of loop diuretics, phenytoin, warfarin, theophylline, or other methylxanthines within 30 days of study entry
  • Use of more than one course of intravenous anti-pseudomonal antibiotics (at least 10 continuous days of medication use) or more than one course of inhaled anti-pseudomonal antibiotics (at least 28 continuous days of medication use) within 2 years of study entry; intravenous or inhaled anti-pseudomonal antibiotics must be stopped at least 30 days prior to study entry
  • Chronic macrolide use (more than 90 day duration) in the 3 months prior to study entry
  • Presence of a condition or abnormality that would compromise the participant's safety or the quality of the study data, in the opinion of the investigator
Both
1 Year to 12 Years
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00097773
169, U01HL080310
Yes
Bonnie Ramsey, Seattle Children's Hospital
Seattle Children's Hospital
  • National Heart, Lung, and Blood Institute (NHLBI)
  • Cystic Fibrosis Foundation
  • CF Therapeutics Development Network Coordinating Center
Principal Investigator: Bonnie W. Ramsey University of Washington
Principal Investigator: George Retsch-Bogart, MD University of North Carolina, Chapel Hill
Principal Investigator: Miriam Treggiari, MD University of Washington
Seattle Children's Hospital
January 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP